Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06225622
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 466
- Registration Number
- NCT06179160
- Locations
- 🇪🇸
Fundacian Jimnez Diaz, Madrid, Spain
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Stanford University, Palo Alto, California, United States
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 33
- Registration Number
- NCT06118047
- Locations
- 🇨🇳
WeiWei Xiao, Guangzhou, Guangdong, China
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Xuekui Liu
- Target Recruit Count
- 52
- Registration Number
- NCT06107114
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06102902
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 410
- Registration Number
- NCT06064877
- Locations
- 🇺🇸
University of California Los Angeles, Westwood, California, United States
🇺🇸MaineHealth Institute for Research, South Portland, Maine, United States
🇺🇸Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT06046482
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT06024174
- Locations
- 🇺🇸
Local Institution - 0025, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0047, Los Angeles, California, United States
🇦🇺Local Institution - 0053, Westmead, New South Wales, Australia
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT06005324
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05985954
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.